Medical Care
Global Mesalamine (Lialda) Market Research Report 2025
- Oct 04, 25
- ID: 507247
- Pages: 83
- Figures: 82
- Views: 7
This report aims to provide a comprehensive presentation of the global market for Mesalamine (Lialda), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesalamine (Lialda).
The Mesalamine (Lialda) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mesalamine (Lialda) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mesalamine (Lialda) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Ferring
AbbVie
Bausch Health
Teva
Mylan
Dr. Reddy's Laboratories
Lupin Limited
Sun Pharma
Sandoz
Dr.Falk Pharma
Zydus Healthcare
Shanghai Pharmaceuticals
Sunflower Pharmaceutical Group
Sinotherapeutics
Segment by Type
Tablets
Capsules
Granule
Suppository
Enema
Others
Segment by Application
Ulcerative Colitis (UC)
Crohn’s Disease (CD)
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalamine (Lialda) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Mesalamine (Lialda) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mesalamine (Lialda) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mesalamine (Lialda) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Ferring
AbbVie
Bausch Health
Teva
Mylan
Dr. Reddy's Laboratories
Lupin Limited
Sun Pharma
Sandoz
Dr.Falk Pharma
Zydus Healthcare
Shanghai Pharmaceuticals
Sunflower Pharmaceutical Group
Sinotherapeutics
Segment by Type
Tablets
Capsules
Granule
Suppository
Enema
Others
Segment by Application
Ulcerative Colitis (UC)
Crohn’s Disease (CD)
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalamine (Lialda) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mesalamine (Lialda) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Granule
1.2.5 Suppository
1.2.6 Enema
1.2.7 Others
1.3 Market by Application
1.3.1 Global Mesalamine (Lialda) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Ulcerative Colitis (UC)
1.3.3 Crohn’s Disease (CD)
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mesalamine (Lialda) Market Perspective (2020-2031)
2.2 Global Mesalamine (Lialda) Growth Trends by Region
2.2.1 Global Mesalamine (Lialda) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Mesalamine (Lialda) Historic Market Size by Region (2020-2025)
2.2.3 Mesalamine (Lialda) Forecasted Market Size by Region (2026-2031)
2.3 Mesalamine (Lialda) Market Dynamics
2.3.1 Mesalamine (Lialda) Industry Trends
2.3.2 Mesalamine (Lialda) Market Drivers
2.3.3 Mesalamine (Lialda) Market Challenges
2.3.4 Mesalamine (Lialda) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mesalamine (Lialda) Players by Revenue
3.1.1 Global Top Mesalamine (Lialda) Players by Revenue (2020-2025)
3.1.2 Global Mesalamine (Lialda) Revenue Market Share by Players (2020-2025)
3.2 Global Top Mesalamine (Lialda) Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Mesalamine (Lialda) Revenue
3.4 Global Mesalamine (Lialda) Market Concentration Ratio
3.4.1 Global Mesalamine (Lialda) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mesalamine (Lialda) Revenue in 2024
3.5 Global Key Players of Mesalamine (Lialda) Head office and Area Served
3.6 Global Key Players of Mesalamine (Lialda), Product and Application
3.7 Global Key Players of Mesalamine (Lialda), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Mesalamine (Lialda) Breakdown Data by Type
4.1 Global Mesalamine (Lialda) Historic Market Size by Type (2020-2025)
4.2 Global Mesalamine (Lialda) Forecasted Market Size by Type (2026-2031)
5 Mesalamine (Lialda) Breakdown Data by Application
5.1 Global Mesalamine (Lialda) Historic Market Size by Application (2020-2025)
5.2 Global Mesalamine (Lialda) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Mesalamine (Lialda) Market Size (2020-2031)
6.2 North America Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Mesalamine (Lialda) Market Size by Country (2020-2025)
6.4 North America Mesalamine (Lialda) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mesalamine (Lialda) Market Size (2020-2031)
7.2 Europe Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Mesalamine (Lialda) Market Size by Country (2020-2025)
7.4 Europe Mesalamine (Lialda) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Mesalamine (Lialda) Market Size (2020-2031)
8.2 Asia-Pacific Mesalamine (Lialda) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2020-2025)
8.4 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Mesalamine (Lialda) Market Size (2020-2031)
9.2 Latin America Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Mesalamine (Lialda) Market Size by Country (2020-2025)
9.4 Latin America Mesalamine (Lialda) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mesalamine (Lialda) Market Size (2020-2031)
10.2 Middle East & Africa Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2020-2025)
10.4 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Mesalamine (Lialda) Introduction
11.1.4 Takeda Revenue in Mesalamine (Lialda) Business (2020-2025)
11.1.5 Takeda Recent Development
11.2 Ferring
11.2.1 Ferring Company Details
11.2.2 Ferring Business Overview
11.2.3 Ferring Mesalamine (Lialda) Introduction
11.2.4 Ferring Revenue in Mesalamine (Lialda) Business (2020-2025)
11.2.5 Ferring Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Mesalamine (Lialda) Introduction
11.3.4 AbbVie Revenue in Mesalamine (Lialda) Business (2020-2025)
11.3.5 AbbVie Recent Development
11.4 Bausch Health
11.4.1 Bausch Health Company Details
11.4.2 Bausch Health Business Overview
11.4.3 Bausch Health Mesalamine (Lialda) Introduction
11.4.4 Bausch Health Revenue in Mesalamine (Lialda) Business (2020-2025)
11.4.5 Bausch Health Recent Development
11.5 Teva
11.5.1 Teva Company Details
11.5.2 Teva Business Overview
11.5.3 Teva Mesalamine (Lialda) Introduction
11.5.4 Teva Revenue in Mesalamine (Lialda) Business (2020-2025)
11.5.5 Teva Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Mesalamine (Lialda) Introduction
11.6.4 Mylan Revenue in Mesalamine (Lialda) Business (2020-2025)
11.6.5 Mylan Recent Development
11.7 Dr. Reddy's Laboratories
11.7.1 Dr. Reddy's Laboratories Company Details
11.7.2 Dr. Reddy's Laboratories Business Overview
11.7.3 Dr. Reddy's Laboratories Mesalamine (Lialda) Introduction
11.7.4 Dr. Reddy's Laboratories Revenue in Mesalamine (Lialda) Business (2020-2025)
11.7.5 Dr. Reddy's Laboratories Recent Development
11.8 Lupin Limited
11.8.1 Lupin Limited Company Details
11.8.2 Lupin Limited Business Overview
11.8.3 Lupin Limited Mesalamine (Lialda) Introduction
11.8.4 Lupin Limited Revenue in Mesalamine (Lialda) Business (2020-2025)
11.8.5 Lupin Limited Recent Development
11.9 Sun Pharma
11.9.1 Sun Pharma Company Details
11.9.2 Sun Pharma Business Overview
11.9.3 Sun Pharma Mesalamine (Lialda) Introduction
11.9.4 Sun Pharma Revenue in Mesalamine (Lialda) Business (2020-2025)
11.9.5 Sun Pharma Recent Development
11.10 Sandoz
11.10.1 Sandoz Company Details
11.10.2 Sandoz Business Overview
11.10.3 Sandoz Mesalamine (Lialda) Introduction
11.10.4 Sandoz Revenue in Mesalamine (Lialda) Business (2020-2025)
11.10.5 Sandoz Recent Development
11.11 Dr.Falk Pharma
11.11.1 Dr.Falk Pharma Company Details
11.11.2 Dr.Falk Pharma Business Overview
11.11.3 Dr.Falk Pharma Mesalamine (Lialda) Introduction
11.11.4 Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2020-2025)
11.11.5 Dr.Falk Pharma Recent Development
11.12 Zydus Healthcare
11.12.1 Zydus Healthcare Company Details
11.12.2 Zydus Healthcare Business Overview
11.12.3 Zydus Healthcare Mesalamine (Lialda) Introduction
11.12.4 Zydus Healthcare Revenue in Mesalamine (Lialda) Business (2020-2025)
11.12.5 Zydus Healthcare Recent Development
11.13 Shanghai Pharmaceuticals
11.13.1 Shanghai Pharmaceuticals Company Details
11.13.2 Shanghai Pharmaceuticals Business Overview
11.13.3 Shanghai Pharmaceuticals Mesalamine (Lialda) Introduction
11.13.4 Shanghai Pharmaceuticals Revenue in Mesalamine (Lialda) Business (2020-2025)
11.13.5 Shanghai Pharmaceuticals Recent Development
11.14 Sunflower Pharmaceutical Group
11.14.1 Sunflower Pharmaceutical Group Company Details
11.14.2 Sunflower Pharmaceutical Group Business Overview
11.14.3 Sunflower Pharmaceutical Group Mesalamine (Lialda) Introduction
11.14.4 Sunflower Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2020-2025)
11.14.5 Sunflower Pharmaceutical Group Recent Development
11.15 Sinotherapeutics
11.15.1 Sinotherapeutics Company Details
11.15.2 Sinotherapeutics Business Overview
11.15.3 Sinotherapeutics Mesalamine (Lialda) Introduction
11.15.4 Sinotherapeutics Revenue in Mesalamine (Lialda) Business (2020-2025)
11.15.5 Sinotherapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mesalamine (Lialda) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Granule
1.2.5 Suppository
1.2.6 Enema
1.2.7 Others
1.3 Market by Application
1.3.1 Global Mesalamine (Lialda) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Ulcerative Colitis (UC)
1.3.3 Crohn’s Disease (CD)
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mesalamine (Lialda) Market Perspective (2020-2031)
2.2 Global Mesalamine (Lialda) Growth Trends by Region
2.2.1 Global Mesalamine (Lialda) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Mesalamine (Lialda) Historic Market Size by Region (2020-2025)
2.2.3 Mesalamine (Lialda) Forecasted Market Size by Region (2026-2031)
2.3 Mesalamine (Lialda) Market Dynamics
2.3.1 Mesalamine (Lialda) Industry Trends
2.3.2 Mesalamine (Lialda) Market Drivers
2.3.3 Mesalamine (Lialda) Market Challenges
2.3.4 Mesalamine (Lialda) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mesalamine (Lialda) Players by Revenue
3.1.1 Global Top Mesalamine (Lialda) Players by Revenue (2020-2025)
3.1.2 Global Mesalamine (Lialda) Revenue Market Share by Players (2020-2025)
3.2 Global Top Mesalamine (Lialda) Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Mesalamine (Lialda) Revenue
3.4 Global Mesalamine (Lialda) Market Concentration Ratio
3.4.1 Global Mesalamine (Lialda) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mesalamine (Lialda) Revenue in 2024
3.5 Global Key Players of Mesalamine (Lialda) Head office and Area Served
3.6 Global Key Players of Mesalamine (Lialda), Product and Application
3.7 Global Key Players of Mesalamine (Lialda), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Mesalamine (Lialda) Breakdown Data by Type
4.1 Global Mesalamine (Lialda) Historic Market Size by Type (2020-2025)
4.2 Global Mesalamine (Lialda) Forecasted Market Size by Type (2026-2031)
5 Mesalamine (Lialda) Breakdown Data by Application
5.1 Global Mesalamine (Lialda) Historic Market Size by Application (2020-2025)
5.2 Global Mesalamine (Lialda) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Mesalamine (Lialda) Market Size (2020-2031)
6.2 North America Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Mesalamine (Lialda) Market Size by Country (2020-2025)
6.4 North America Mesalamine (Lialda) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mesalamine (Lialda) Market Size (2020-2031)
7.2 Europe Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Mesalamine (Lialda) Market Size by Country (2020-2025)
7.4 Europe Mesalamine (Lialda) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Mesalamine (Lialda) Market Size (2020-2031)
8.2 Asia-Pacific Mesalamine (Lialda) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2020-2025)
8.4 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Mesalamine (Lialda) Market Size (2020-2031)
9.2 Latin America Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Mesalamine (Lialda) Market Size by Country (2020-2025)
9.4 Latin America Mesalamine (Lialda) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mesalamine (Lialda) Market Size (2020-2031)
10.2 Middle East & Africa Mesalamine (Lialda) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2020-2025)
10.4 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Mesalamine (Lialda) Introduction
11.1.4 Takeda Revenue in Mesalamine (Lialda) Business (2020-2025)
11.1.5 Takeda Recent Development
11.2 Ferring
11.2.1 Ferring Company Details
11.2.2 Ferring Business Overview
11.2.3 Ferring Mesalamine (Lialda) Introduction
11.2.4 Ferring Revenue in Mesalamine (Lialda) Business (2020-2025)
11.2.5 Ferring Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Mesalamine (Lialda) Introduction
11.3.4 AbbVie Revenue in Mesalamine (Lialda) Business (2020-2025)
11.3.5 AbbVie Recent Development
11.4 Bausch Health
11.4.1 Bausch Health Company Details
11.4.2 Bausch Health Business Overview
11.4.3 Bausch Health Mesalamine (Lialda) Introduction
11.4.4 Bausch Health Revenue in Mesalamine (Lialda) Business (2020-2025)
11.4.5 Bausch Health Recent Development
11.5 Teva
11.5.1 Teva Company Details
11.5.2 Teva Business Overview
11.5.3 Teva Mesalamine (Lialda) Introduction
11.5.4 Teva Revenue in Mesalamine (Lialda) Business (2020-2025)
11.5.5 Teva Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Mesalamine (Lialda) Introduction
11.6.4 Mylan Revenue in Mesalamine (Lialda) Business (2020-2025)
11.6.5 Mylan Recent Development
11.7 Dr. Reddy's Laboratories
11.7.1 Dr. Reddy's Laboratories Company Details
11.7.2 Dr. Reddy's Laboratories Business Overview
11.7.3 Dr. Reddy's Laboratories Mesalamine (Lialda) Introduction
11.7.4 Dr. Reddy's Laboratories Revenue in Mesalamine (Lialda) Business (2020-2025)
11.7.5 Dr. Reddy's Laboratories Recent Development
11.8 Lupin Limited
11.8.1 Lupin Limited Company Details
11.8.2 Lupin Limited Business Overview
11.8.3 Lupin Limited Mesalamine (Lialda) Introduction
11.8.4 Lupin Limited Revenue in Mesalamine (Lialda) Business (2020-2025)
11.8.5 Lupin Limited Recent Development
11.9 Sun Pharma
11.9.1 Sun Pharma Company Details
11.9.2 Sun Pharma Business Overview
11.9.3 Sun Pharma Mesalamine (Lialda) Introduction
11.9.4 Sun Pharma Revenue in Mesalamine (Lialda) Business (2020-2025)
11.9.5 Sun Pharma Recent Development
11.10 Sandoz
11.10.1 Sandoz Company Details
11.10.2 Sandoz Business Overview
11.10.3 Sandoz Mesalamine (Lialda) Introduction
11.10.4 Sandoz Revenue in Mesalamine (Lialda) Business (2020-2025)
11.10.5 Sandoz Recent Development
11.11 Dr.Falk Pharma
11.11.1 Dr.Falk Pharma Company Details
11.11.2 Dr.Falk Pharma Business Overview
11.11.3 Dr.Falk Pharma Mesalamine (Lialda) Introduction
11.11.4 Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2020-2025)
11.11.5 Dr.Falk Pharma Recent Development
11.12 Zydus Healthcare
11.12.1 Zydus Healthcare Company Details
11.12.2 Zydus Healthcare Business Overview
11.12.3 Zydus Healthcare Mesalamine (Lialda) Introduction
11.12.4 Zydus Healthcare Revenue in Mesalamine (Lialda) Business (2020-2025)
11.12.5 Zydus Healthcare Recent Development
11.13 Shanghai Pharmaceuticals
11.13.1 Shanghai Pharmaceuticals Company Details
11.13.2 Shanghai Pharmaceuticals Business Overview
11.13.3 Shanghai Pharmaceuticals Mesalamine (Lialda) Introduction
11.13.4 Shanghai Pharmaceuticals Revenue in Mesalamine (Lialda) Business (2020-2025)
11.13.5 Shanghai Pharmaceuticals Recent Development
11.14 Sunflower Pharmaceutical Group
11.14.1 Sunflower Pharmaceutical Group Company Details
11.14.2 Sunflower Pharmaceutical Group Business Overview
11.14.3 Sunflower Pharmaceutical Group Mesalamine (Lialda) Introduction
11.14.4 Sunflower Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2020-2025)
11.14.5 Sunflower Pharmaceutical Group Recent Development
11.15 Sinotherapeutics
11.15.1 Sinotherapeutics Company Details
11.15.2 Sinotherapeutics Business Overview
11.15.3 Sinotherapeutics Mesalamine (Lialda) Introduction
11.15.4 Sinotherapeutics Revenue in Mesalamine (Lialda) Business (2020-2025)
11.15.5 Sinotherapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Mesalamine (Lialda) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Tablets
Table 3. Key Players of Capsules
Table 4. Key Players of Granule
Table 5. Key Players of Suppository
Table 6. Key Players of Enema
Table 7. Key Players of Others
Table 8. Global Mesalamine (Lialda) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Mesalamine (Lialda) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Mesalamine (Lialda) Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Mesalamine (Lialda) Market Share by Region (2020-2025)
Table 12. Global Mesalamine (Lialda) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Mesalamine (Lialda) Market Share by Region (2026-2031)
Table 14. Mesalamine (Lialda) Market Trends
Table 15. Mesalamine (Lialda) Market Drivers
Table 16. Mesalamine (Lialda) Market Challenges
Table 17. Mesalamine (Lialda) Market Restraints
Table 18. Global Mesalamine (Lialda) Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Mesalamine (Lialda) Market Share by Players (2020-2025)
Table 20. Global Top Mesalamine (Lialda) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesalamine (Lialda) as of 2024)
Table 21. Ranking of Global Top Mesalamine (Lialda) Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Mesalamine (Lialda) Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Mesalamine (Lialda), Headquarters and Area Served
Table 24. Global Key Players of Mesalamine (Lialda), Product and Application
Table 25. Global Key Players of Mesalamine (Lialda), Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Mesalamine (Lialda) Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Mesalamine (Lialda) Revenue Market Share by Type (2020-2025)
Table 29. Global Mesalamine (Lialda) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Mesalamine (Lialda) Revenue Market Share by Type (2026-2031)
Table 31. Global Mesalamine (Lialda) Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Mesalamine (Lialda) Revenue Market Share by Application (2020-2025)
Table 33. Global Mesalamine (Lialda) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Mesalamine (Lialda) Revenue Market Share by Application (2026-2031)
Table 35. North America Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Mesalamine (Lialda) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Mesalamine (Lialda) Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Mesalamine (Lialda) Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 50. Takeda Company Details
Table 51. Takeda Business Overview
Table 52. Takeda Mesalamine (Lialda) Product
Table 53. Takeda Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 54. Takeda Recent Development
Table 55. Ferring Company Details
Table 56. Ferring Business Overview
Table 57. Ferring Mesalamine (Lialda) Product
Table 58. Ferring Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 59. Ferring Recent Development
Table 60. AbbVie Company Details
Table 61. AbbVie Business Overview
Table 62. AbbVie Mesalamine (Lialda) Product
Table 63. AbbVie Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 64. AbbVie Recent Development
Table 65. Bausch Health Company Details
Table 66. Bausch Health Business Overview
Table 67. Bausch Health Mesalamine (Lialda) Product
Table 68. Bausch Health Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 69. Bausch Health Recent Development
Table 70. Teva Company Details
Table 71. Teva Business Overview
Table 72. Teva Mesalamine (Lialda) Product
Table 73. Teva Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 74. Teva Recent Development
Table 75. Mylan Company Details
Table 76. Mylan Business Overview
Table 77. Mylan Mesalamine (Lialda) Product
Table 78. Mylan Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 79. Mylan Recent Development
Table 80. Dr. Reddy's Laboratories Company Details
Table 81. Dr. Reddy's Laboratories Business Overview
Table 82. Dr. Reddy's Laboratories Mesalamine (Lialda) Product
Table 83. Dr. Reddy's Laboratories Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 84. Dr. Reddy's Laboratories Recent Development
Table 85. Lupin Limited Company Details
Table 86. Lupin Limited Business Overview
Table 87. Lupin Limited Mesalamine (Lialda) Product
Table 88. Lupin Limited Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 89. Lupin Limited Recent Development
Table 90. Sun Pharma Company Details
Table 91. Sun Pharma Business Overview
Table 92. Sun Pharma Mesalamine (Lialda) Product
Table 93. Sun Pharma Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 94. Sun Pharma Recent Development
Table 95. Sandoz Company Details
Table 96. Sandoz Business Overview
Table 97. Sandoz Mesalamine (Lialda) Product
Table 98. Sandoz Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 99. Sandoz Recent Development
Table 100. Dr.Falk Pharma Company Details
Table 101. Dr.Falk Pharma Business Overview
Table 102. Dr.Falk Pharma Mesalamine (Lialda) Product
Table 103. Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 104. Dr.Falk Pharma Recent Development
Table 105. Zydus Healthcare Company Details
Table 106. Zydus Healthcare Business Overview
Table 107. Zydus Healthcare Mesalamine (Lialda) Product
Table 108. Zydus Healthcare Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 109. Zydus Healthcare Recent Development
Table 110. Shanghai Pharmaceuticals Company Details
Table 111. Shanghai Pharmaceuticals Business Overview
Table 112. Shanghai Pharmaceuticals Mesalamine (Lialda) Product
Table 113. Shanghai Pharmaceuticals Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 114. Shanghai Pharmaceuticals Recent Development
Table 115. Sunflower Pharmaceutical Group Company Details
Table 116. Sunflower Pharmaceutical Group Business Overview
Table 117. Sunflower Pharmaceutical Group Mesalamine (Lialda) Product
Table 118. Sunflower Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 119. Sunflower Pharmaceutical Group Recent Development
Table 120. Sinotherapeutics Company Details
Table 121. Sinotherapeutics Business Overview
Table 122. Sinotherapeutics Mesalamine (Lialda) Product
Table 123. Sinotherapeutics Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 124. Sinotherapeutics Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Authors List of This Report
List of Figures
Figure 1. Mesalamine (Lialda) Picture
Figure 2. Global Mesalamine (Lialda) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Mesalamine (Lialda) Market Share by Type: 2024 VS 2031
Figure 4. Tablets Features
Figure 5. Capsules Features
Figure 6. Granule Features
Figure 7. Suppository Features
Figure 8. Enema Features
Figure 9. Others Features
Figure 10. Global Mesalamine (Lialda) Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Mesalamine (Lialda) Market Share by Application: 2024 VS 2031
Figure 12. Ulcerative Colitis (UC) Case Studies
Figure 13. Crohn’s Disease (CD) Case Studies
Figure 14. Others Case Studies
Figure 15. Mesalamine (Lialda) Report Years Considered
Figure 16. Global Mesalamine (Lialda) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Mesalamine (Lialda) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Mesalamine (Lialda) Market Share by Region: 2024 VS 2031
Figure 19. Global Mesalamine (Lialda) Market Share by Players in 2024
Figure 20. Global Mesalamine (Lialda) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by Mesalamine (Lialda) Revenue in 2024
Figure 22. North America Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 24. United States Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 28. Germany Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Ireland Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Mesalamine (Lialda) Market Share by Region (2020-2031)
Figure 36. China Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia & New Zealand Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 44. Mexico Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 48. Israel Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Takeda Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 52. Ferring Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 53. AbbVie Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 54. Bausch Health Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 55. Teva Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 56. Mylan Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 57. Dr. Reddy's Laboratories Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 58. Lupin Limited Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 59. Sun Pharma Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 60. Sandoz Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 61. Dr.Falk Pharma Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 62. Zydus Healthcare Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 63. Shanghai Pharmaceuticals Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 64. Sunflower Pharmaceutical Group Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 65. Sinotherapeutics Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Table 1. Global Mesalamine (Lialda) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Tablets
Table 3. Key Players of Capsules
Table 4. Key Players of Granule
Table 5. Key Players of Suppository
Table 6. Key Players of Enema
Table 7. Key Players of Others
Table 8. Global Mesalamine (Lialda) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Mesalamine (Lialda) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Mesalamine (Lialda) Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Mesalamine (Lialda) Market Share by Region (2020-2025)
Table 12. Global Mesalamine (Lialda) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Mesalamine (Lialda) Market Share by Region (2026-2031)
Table 14. Mesalamine (Lialda) Market Trends
Table 15. Mesalamine (Lialda) Market Drivers
Table 16. Mesalamine (Lialda) Market Challenges
Table 17. Mesalamine (Lialda) Market Restraints
Table 18. Global Mesalamine (Lialda) Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Mesalamine (Lialda) Market Share by Players (2020-2025)
Table 20. Global Top Mesalamine (Lialda) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesalamine (Lialda) as of 2024)
Table 21. Ranking of Global Top Mesalamine (Lialda) Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Mesalamine (Lialda) Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Mesalamine (Lialda), Headquarters and Area Served
Table 24. Global Key Players of Mesalamine (Lialda), Product and Application
Table 25. Global Key Players of Mesalamine (Lialda), Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Mesalamine (Lialda) Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Mesalamine (Lialda) Revenue Market Share by Type (2020-2025)
Table 29. Global Mesalamine (Lialda) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Mesalamine (Lialda) Revenue Market Share by Type (2026-2031)
Table 31. Global Mesalamine (Lialda) Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Mesalamine (Lialda) Revenue Market Share by Application (2020-2025)
Table 33. Global Mesalamine (Lialda) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Mesalamine (Lialda) Revenue Market Share by Application (2026-2031)
Table 35. North America Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Mesalamine (Lialda) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Mesalamine (Lialda) Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Mesalamine (Lialda) Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Mesalamine (Lialda) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Mesalamine (Lialda) Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Mesalamine (Lialda) Market Size by Country (2026-2031) & (US$ Million)
Table 50. Takeda Company Details
Table 51. Takeda Business Overview
Table 52. Takeda Mesalamine (Lialda) Product
Table 53. Takeda Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 54. Takeda Recent Development
Table 55. Ferring Company Details
Table 56. Ferring Business Overview
Table 57. Ferring Mesalamine (Lialda) Product
Table 58. Ferring Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 59. Ferring Recent Development
Table 60. AbbVie Company Details
Table 61. AbbVie Business Overview
Table 62. AbbVie Mesalamine (Lialda) Product
Table 63. AbbVie Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 64. AbbVie Recent Development
Table 65. Bausch Health Company Details
Table 66. Bausch Health Business Overview
Table 67. Bausch Health Mesalamine (Lialda) Product
Table 68. Bausch Health Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 69. Bausch Health Recent Development
Table 70. Teva Company Details
Table 71. Teva Business Overview
Table 72. Teva Mesalamine (Lialda) Product
Table 73. Teva Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 74. Teva Recent Development
Table 75. Mylan Company Details
Table 76. Mylan Business Overview
Table 77. Mylan Mesalamine (Lialda) Product
Table 78. Mylan Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 79. Mylan Recent Development
Table 80. Dr. Reddy's Laboratories Company Details
Table 81. Dr. Reddy's Laboratories Business Overview
Table 82. Dr. Reddy's Laboratories Mesalamine (Lialda) Product
Table 83. Dr. Reddy's Laboratories Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 84. Dr. Reddy's Laboratories Recent Development
Table 85. Lupin Limited Company Details
Table 86. Lupin Limited Business Overview
Table 87. Lupin Limited Mesalamine (Lialda) Product
Table 88. Lupin Limited Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 89. Lupin Limited Recent Development
Table 90. Sun Pharma Company Details
Table 91. Sun Pharma Business Overview
Table 92. Sun Pharma Mesalamine (Lialda) Product
Table 93. Sun Pharma Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 94. Sun Pharma Recent Development
Table 95. Sandoz Company Details
Table 96. Sandoz Business Overview
Table 97. Sandoz Mesalamine (Lialda) Product
Table 98. Sandoz Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 99. Sandoz Recent Development
Table 100. Dr.Falk Pharma Company Details
Table 101. Dr.Falk Pharma Business Overview
Table 102. Dr.Falk Pharma Mesalamine (Lialda) Product
Table 103. Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 104. Dr.Falk Pharma Recent Development
Table 105. Zydus Healthcare Company Details
Table 106. Zydus Healthcare Business Overview
Table 107. Zydus Healthcare Mesalamine (Lialda) Product
Table 108. Zydus Healthcare Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 109. Zydus Healthcare Recent Development
Table 110. Shanghai Pharmaceuticals Company Details
Table 111. Shanghai Pharmaceuticals Business Overview
Table 112. Shanghai Pharmaceuticals Mesalamine (Lialda) Product
Table 113. Shanghai Pharmaceuticals Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 114. Shanghai Pharmaceuticals Recent Development
Table 115. Sunflower Pharmaceutical Group Company Details
Table 116. Sunflower Pharmaceutical Group Business Overview
Table 117. Sunflower Pharmaceutical Group Mesalamine (Lialda) Product
Table 118. Sunflower Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 119. Sunflower Pharmaceutical Group Recent Development
Table 120. Sinotherapeutics Company Details
Table 121. Sinotherapeutics Business Overview
Table 122. Sinotherapeutics Mesalamine (Lialda) Product
Table 123. Sinotherapeutics Revenue in Mesalamine (Lialda) Business (2020-2025) & (US$ Million)
Table 124. Sinotherapeutics Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Authors List of This Report
List of Figures
Figure 1. Mesalamine (Lialda) Picture
Figure 2. Global Mesalamine (Lialda) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Mesalamine (Lialda) Market Share by Type: 2024 VS 2031
Figure 4. Tablets Features
Figure 5. Capsules Features
Figure 6. Granule Features
Figure 7. Suppository Features
Figure 8. Enema Features
Figure 9. Others Features
Figure 10. Global Mesalamine (Lialda) Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Mesalamine (Lialda) Market Share by Application: 2024 VS 2031
Figure 12. Ulcerative Colitis (UC) Case Studies
Figure 13. Crohn’s Disease (CD) Case Studies
Figure 14. Others Case Studies
Figure 15. Mesalamine (Lialda) Report Years Considered
Figure 16. Global Mesalamine (Lialda) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Mesalamine (Lialda) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Mesalamine (Lialda) Market Share by Region: 2024 VS 2031
Figure 19. Global Mesalamine (Lialda) Market Share by Players in 2024
Figure 20. Global Mesalamine (Lialda) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by Mesalamine (Lialda) Revenue in 2024
Figure 22. North America Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 24. United States Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 28. Germany Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Ireland Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Mesalamine (Lialda) Market Share by Region (2020-2031)
Figure 36. China Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia & New Zealand Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 44. Mexico Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Mesalamine (Lialda) Market Share by Country (2020-2031)
Figure 48. Israel Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Mesalamine (Lialda) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Takeda Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 52. Ferring Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 53. AbbVie Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 54. Bausch Health Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 55. Teva Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 56. Mylan Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 57. Dr. Reddy's Laboratories Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 58. Lupin Limited Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 59. Sun Pharma Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 60. Sandoz Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 61. Dr.Falk Pharma Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 62. Zydus Healthcare Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 63. Shanghai Pharmaceuticals Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 64. Sunflower Pharmaceutical Group Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 65. Sinotherapeutics Revenue Growth Rate in Mesalamine (Lialda) Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Spatial Metabolomics Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global Pharmaceutical Process Analytical Technology (PAT) Software Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global HASE Rheology Modifiers Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232